Keytruda (Pembrolizumab) Patent Expiration, LOE Window & CMS Spending

Keytruda (Pembrolizumab) by Merck & Co.: Biologic BLA (Purple Book Regime), 0 AB generics, $969.5M 2024 CMS Part D & Medicaid spend, and $24,063 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayB125514 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$969.5M
2024 Medicare Part D Spend$140.1M
2024 Medicaid Spend$829.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($24,063 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.